Drug Profile
Research programme: ophthalmology therapeutic - Santen Pharmaceuticals/University College of London
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Santen Pharmaceutical
- Developer Santen Pharmaceutical; University College London
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Eye-disorders in United Kingdom (Ophthalmic)
- 03 Aug 2016 Santen Pharmaceuticals and University College of London enter into a research collaboration
- 03 Aug 2016 Early research in Eye disorders in United Kingdom (Ophthalmic)